Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 2, 2014, Pages 208-217

  Corte, Tamera J ^a,b   Keir, Gregory J ^a,c   Dimopoulos, Konstantino ^d   Howard, Luk ^e   Corris, Paul A ^f   Parfitt, Lis ^d   Foley, Clair ^d   Yanez Lopez, Monic ^d   Babalis, Daphn ^d   Marino, Phili ^d   Maher, Toby M ^a   Renzoni, Elizabeth A ^a   Spencer, Lis ^g   Elliot, Charlie A ^h   Birring, Surinder S ⁱ   O'Reilly, Katherin ^j   Gatzoulis, Michael A ^d   Wells, Athol U ^a   Wort, Stephen J ^d,k  

^a Interstitial Lung Disease Unit   (United Kingdom)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

^j SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^k NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

Clinical trial; Hypertension; Interstitial lung diseases; Pulmonary

Indexed keywords

BOSENTAN; PLACEBO; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

AGED; ANXIETY DISORDER; ARTICLE; CELLULITIS; CHEST INFECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FLUSHING; HEARING IMPAIRMENT; HEART FAILURE; HEART INDEX; HUMAN; HYPERCAPNIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; LUNG ARTERY PRESSURE; LUNG CARCINOMA; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HYPERTENSION; INTERSTITIAL LUNG DISEASES; INTERSTITIAL PNEUMONIA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PULMONARY; VASCULAR RESISTANCE; VERY ELDERLY; YOUNG ADULT;

CLINICAL TRIAL; HYPERTENSION; INTERSTITIAL LUNG DISEASES; PULMONARY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84906922433     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0446OC     Document Type: Article

References (31)

1. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 2012;106:1613-1621.
2. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-752.
3. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007;30:715-721.
4. Yang SJ, Hoffman C, Mulligan K. Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation. Proc Am Thorac Soc 2006;3:A369.
5. Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest 2013;144:564-570.
6. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009;64:883-888.
7. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131: 897-899.
8. Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, Leuchte HH, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013;41: 853-860.
9. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013;143:1699-1708.
10. Günther A, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stähler G, Seeger W, Grimminger F, Leconte I, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007;29:713-719.
11. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
12. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156:600-608.
13. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
14. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371: 2093-2100.
15. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
16. Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 2006;36:44-48.
17. Keir GJ, Corte TJ, Parfitt L, Maher T, Marino P, Renzoni E, Dimopoulos K, Gatzoulis M, Madden B, Howard L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia: a randomized, double-blind, placebo-controlled study. Eur Respir J 2013;42:A1779.
18. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167: 962-969.
19. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168: 538-542.
20. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, Wells AU. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010;36: 819-825.
21. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, et al.; ARTEMIS-IPF Investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013;158: 641-649.
22. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007;131:657-663.
23. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25, Suppl)D34-D41.
24. Baughman RP, Culver DA, Cordorva FC, Padilla M, Gibson KF, Lower EL, Engel PJ. Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014;145:810-817.
25. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
26. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
27. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184: 92-99.
28. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360: 895-900.
29. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-628.
30. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, Kawut SM. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012;9:268-275.
31. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.